METiS Technologies is a company based in Beijing, China. It uses AI to develop advanced drug delivery systems with nanotechnology.
The company has raised 400 million RMB in Series D funding.
The Beijing Medical and Health Industry Investment Fund and the Daxing Industrial Investment Fund led the funding round.
The company plans to use the funding to speed up its main strategic goals, such as upgrading its automated technology platform and developing its products.
It also aims to grow global partnerships and hire new talent to support its expansion.
METiS Technologies is led by CEO Dr. Chris Lai. The company creates platforms that use AI to simulate and understand how tiny materials (nanomaterials) behave.
This helps in designing, improving, and testing new nanomaterials and the drugs they carry in a smarter and faster way.
By using this advanced technology, METiS aims to develop better treatments for many diseases like cancer, metabolic and autoimmune disorders, and brain-related conditions, to improve people’s health.
As a key part of this effort, METiS launched the OpenCGT platform to tackle major challenges in precise nanodelivery.
The platform also aims to lower costs and complexity, and help bring new cell and gene therapies (CGT) into clinical use.
METiS Technologies is using AI and nanotechnology to build a healthier world. The company is a leader in combining artificial intelligence with nanoscience to improve how drugs and other active agents are delivered in humans and other life forms.
By advancing this AI-powered nanotech, METiS hopes to create better treatments for serious diseases like cancer, metabolic and autoimmune disorders, and brain-related conditions — ultimately aiming to improve health around the world.
Read more- Kotoba Technologies Secures $11.83M in Seed 2 Funding to Advance AI Speech Technology
